TYK Medicines Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	0.11	-	44.24
Cost of Revenue	0.09	-	24.2
Gross Profit	0.01	-	20.04
Selling, General & Admin	108.33	59.31	33.54
Research & Development	235.45	249.25	229.81
Operating Expenses	343.78	308.56	263.35
Operating Income	-343.76	-308.56	-243.31
Interest Expense	-12.57	-8.73	-3.26
Interest & Investment Income	3.28	3.73	7.37
Currency Exchange Gain (Loss)	0.29	0.1	-
Other Non Operating Income (Expenses)	-35.21	-68.98	-72.87
EBT Excluding Unusual Items	-387.97	-382.44	-312.06
Gain (Loss) on Sale of Investments	-0	-0.73	0.34
Gain (Loss) on Sale of Assets	0.04	-0.01	-0.04
Other Unusual Items	0	0.01	-0.05
Pretax Income	-387.93	-383.17	-311.8
Earnings From Continuing Operations	-387.93	-383.17	-311.8
Minority Interest in Earnings	0.97	0.74	0.81
Net Income	-386.96	-382.43	-310.99
Net Income to Common	-386.96	-382.43	-310.99
Shares Outstanding (Basic)	-	289	278
Shares Outstanding (Diluted)	-	289	278
Shares Change (YoY)	-	3.94%	-
EPS (Basic)	-	-1.32	-1.12
EPS (Diluted)	-	-1.32	-1.12
Free Cash Flow	-	-277.32	-279.02
Free Cash Flow Per Share	-	-0.96	-1.00
Gross Margin	13.08%	-	45.30%
Operating Margin	-321274.77%	-	-549.94%
Profit Margin	-361640.19%	-	-702.94%
Free Cash Flow Margin	-	-	-630.67%
EBITDA	-330.31	-295.1	-232.31
D&A For EBITDA	13.46	13.46	11
EBIT	-343.76	-308.56	-243.31

Updated Sep 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.